Author(s): Airavaara M, Harvey BK, Voutilainen MH, Shen H, Chou J, et al.
Cerebral dopamine neurotrophic factor (CDNF) is a recently discovered protein, which belongs to the evolutionarily conserved CDNF/MANF family of neurotrophic factors. The degeneration of dopamine neurons following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment is well characterized, and efficacy in this model is considered a standard criterion for development of parkinsonian therapies. MPTP is a neurotoxin, which produces parkinsonian symptoms in humans and in C57/Bl6 mice. To date, there are no reports about the effects of CDNF on dopamine neuron survival or function in the MPTP rodent model, a critical gap. Therefore, we studied whether CDNF has neuroprotective and neurorestorative properties for the nigrostriatal dopamine system after MPTP injections in C57/Bl6 mice. We found that bilateral striatal CDNF injections, given 20 h before MPTP, improved horizontal and vertical motor behavior. CDNF pretreatment increased tyrosine hydroxylase (TH) immunoreactivity in the striatum and in the substantia nigra pars reticulata (SNpr), as well as the number of TH-positive cells in substantia nigra pars compacta (SNpc). Posttreatment with CDNF, given 1 week after MPTP injections, increased horizontal and vertical motor behavior of mice, as well as dopamine fiber densities in the striatum and the number of TH-positive cells in SNpc. CDNF did not alter any of the analyzed dopaminergic biomarkers or locomotor behavior in MPTP-untreated animals. We conclude that striatal CDNF administration is both neuroprotective and neurorestorative for the TH-positive cells in the nigrostriatal dopamine system in the MPTP model, which supports the development of CDNF-based treatment for Parkinson's disease.
Referred From: https://www.ncbi.nlm.nih.gov/pubmed/21943517
Author(s): Lee MA, Walker RW, Hildreth TJ, Prentice WM
Author(s): Bair MJ, Robinson RL, Katon W, Kroenke K
Author(s): McWilliams LA, Cox BJ, Enns MW
Author(s): Hanagasi HA, Akat S, Gurvit H, Yazici J, Emre M
Author(s): Nieoullon A
Author(s): Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, et al.
Author(s): Roh JH, Kim BJ, Jang JH, Seo WK, Lee SH, et al.
Author(s): Hara T, Hirayama M, Mizutani Y, Hama T, Hori N, et al.
Author(s): Erro R, Santangelo G, Picillo M, Vitale C, Amboni M, et al.
Author(s): Hughes AJ, Daniel SE, Kilford L, Lees AJ
Author(s): Fahn S; Parkinson Study Group
Author(s): Nie K, Zhang Y, Wang L, Zhao J, Huang Z, et al.
Author(s): Chaudhuri KR, Martinez-Martin P, Schapira AH, Stocchi F, Sethi K, et al.
Author(s): Melzack R
Author(s): Cleeland CS, Ryan KM
Author(s): Smeding HM, Esselink RA, Schmand B, Koning-Haanstra M, Nijhuis I, et al.
Author(s): Ford B
Author(s): Ha AD, Jankovic J
Author(s): Santos-García D, Abella-Corral J, Aneiros-Díaz Á, Santos-Canelles H, Llaneza-González MA, et al.
Author(s): Yong MH, Allen JC Jr, Prakash KM, Tan EK
Author(s): Jarcho JM, Mayer EA, Jiang ZK, Feier NA, London ED
Author(s): Mylius V, Brebbermann J, Dohmann H, Engau I, Oertel WH, et al.
Author(s): Nutt JG
Author(s): Lim SY, Farrell MJ, Gibson SJ, Helme RD, Lang AE, et al.
Author(s): Romenets SR, Wolfson C, Galatas C, Pelletier A, Altman R, et al.
Author(s): Raudino F